Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.

Ann Neurol · 2019 · PMC6593762 · PMID 30802998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Dyskinesia responded to reductions in antiparkinsonian medications, and diary data showed a trend toward improvements in troublesome and nontroublesome dyskinesia (Fig 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.